Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland.
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):522-530. doi: 10.1158/1055-9965.EPI-18-0784. Epub 2018 Nov 21.
Brain and other central nervous system (CNS) cancers are the leading cause of U.S. pediatric cancer mortality. Incidence trends can provide etiologic insight. We report trends in incidence rates of pediatric malignant CNS cancers and pilocytic astrocytoma (nonmalignant but historically registered) in the United States.
Age-standardized incidence rates and annual percent changes (APC) in rates during 1998 to 2013 were calculated for children aged 0 to 19, stratified by subtype, age, sex, and for gliomas, histology and location. We estimated the absolute change in number of cases diagnosed U.S.-wide during 2013 compared with the expected number of cases had 1998 rates remained stable.
Rates of all pediatric malignant CNS cancer combined ( = 18,612) did not change [APC: 0.16; 95% confidence interval (CI): -0.21-0.53]. There were statistically significant changes in several subtypes; however, glioma incidence ( = 10,664) increased by 0.77% per year (95% CI: 0.29-1.26), embryonal cancer rates ( = 5,423) decreased by 0.88% per year (95% CI: -1.33 to -0.43), and pilocytic astrocytoma rates ( = 6,858) increased by 0.89% per year (95% CI: 0.21-1.58). Of the 1,171 malignant tumors and 450 pilocytic astrocytomas diagnosed in U.S. children in 2013, we estimated 120 excess gliomas, 94 excess pilocytic astrocytomas, and 72 fewer embryonal CNS tumors than would be expected had 1998 rates remained stable.
The gradual changes in incidence we observed for specific types of pediatric CNS cancers are likely due to a combination of changes in classification and diagnosis and true changes in CNS cancer.
Continued surveillance of pediatric CNS tumors should remain a priority, given their significant contribution to pediatric cancer-related deaths.
脑和其他中枢神经系统(CNS)癌症是美国儿童癌症死亡的主要原因。发病趋势可为病因学提供线索。我们报告了美国儿童恶性 CNS 癌症和毛细胞星形细胞瘤(非恶性但历史上有登记)发病率趋势。
对 1998 年至 2013 年期间 0 至 19 岁儿童的亚组、年龄、性别和神经胶质瘤的亚型、组织学和位置进行了年龄标准化发病率和年百分变化(APC)的计算。我们估计了 2013 年与预期病例数相比,美国范围内诊断出的病例数的绝对变化,如果 1998 年的发病率保持稳定。
所有儿童恶性 CNS 癌症的合并发病率(=18612)没有变化[APC:0.16;95%置信区间(CI):-0.21-0.53]。几个亚型的发病率发生了统计学上的显著变化;然而,神经胶质瘤的发病率(=10664)每年增加 0.77%(95%CI:0.29-1.26),胚胎癌的发病率(=5423)每年下降 0.88%(95%CI:-1.33-0.43),毛细胞星形细胞瘤的发病率(=6858)每年增加 0.89%(95%CI:0.21-1.58)。在 2013 年美国儿童中诊断出的 1171 例恶性肿瘤和 450 例毛细胞星形细胞瘤中,我们估计有 120 例额外的神经胶质瘤、94 例额外的毛细胞星形细胞瘤和 72 例胚胎性 CNS 肿瘤少于 1998 年的发病率保持稳定。
我们观察到特定类型的儿童 CNS 癌症发病率的逐渐变化,可能是由于分类和诊断的变化以及 CNS 癌症的真正变化的综合作用。
鉴于其对儿童癌症相关死亡的重大贡献,继续监测儿童 CNS 肿瘤应仍是一个优先事项。